Track market-moving stories before they get noisy

Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company's stock after selling 2,975,000 shares during the period.

Posted by Defense World Staff on Apr 6th, 2026

Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 210,674 shares of the biopharmaceutical company’s stock, valued at approximately $3,000,000. Capricorn Fund Managers Ltd owned about 0.07% of Amicus Therapeutics at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in FOLD. Goldman Sachs Group Inc. boosted its stake in Amicus Therapeutics by 7.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company’s stock valued at $22,061,000 after purchasing an additional 194,213 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Amicus Therapeutics by 11.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company’s stock worth $8,751,000 after buying an additional 113,803 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Amicus Therapeutics by 37.1% during the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company’s stock worth $1,395,000 after buying an additional 46,218 shares in the last quarter. Strs Ohio bought a new stake in shares of Amicus Therapeutics in the first quarter valued at about $30,000. Finally, Cetera Investment Advisers bought a new stake in shares of Amicus Therapeutics in the second quarter valued at about $79,000.

Amicus Therapeutics Stock Performance Shares of Amicus Therapeutics stock opened at $14.44 on Monday. The company has a market capitalization of $4.53 billion, a price-to-earnings ratio of -180.50 and a beta of 0.48. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $14.46. The firm’s 50-day moving average price is $14.35 and its two-hundred day moving average price is $11.89.

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last issued its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The firm had revenue of $185.21 million during the quarter, compared to analyst estimates of $185.00 million. During the same quarter in the previous year, the firm posted $0.09 earnings per share. Amicus Therapeutics’s quarterly revenue was up 23.7% compared to the same quarter last year. On average, analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Insider Buying and Selling In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the sale, the chief executive officer directly owned 1,021,180 shares in the company, valued at $14,613,085.80. This represents a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In A number of equities analysts recently commented on the stock. Guggenheim lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Jefferies Financial Group restated a “hold” rating and set a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Leerink Partners cut shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $17.00 to $14.50 in a report on Monday, December 29th. TD Cowen cut Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price target for the company. in a research note on Monday, December 22nd. Finally, Zacks Research downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $15.39.

View Our Latest Analysis on Amicus Therapeutics

About Amicus Therapeutics (Free Report)

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

Featured Stories Five stocks we like better than Amicus Therapeutics

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECapricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA

NEXT HEADLINE »JPMorgan Chase & Co. Has $2.71 Million Holdings in Akebia Therapeutics, Inc. $AKBA

BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects.